1. Effect of Hepatic or Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Ponesimod, a Selective S1P1 Receptor Modulator. Issue 5 (10th December 2015) Authors: Guérard, Nicolas; Zwingelstein, Christian; Hoch, Matthias; Dingemanse, Jasper Journal: Basic & clinical pharmacology & toxicology Issue: Volume 118:Issue 5(2016) Page Start: 356 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function Impairment. (15th June 2017) Authors: Guérard, Nicolas; Zwingelstein, Christian; Dingemanse, Jasper Journal: Journal of clinical pharmacology Issue: Volume 57:Number 11(2017) Page Start: 1425 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement. Issue 4 (28th August 2017) Authors: Guérard, Nicolas; Oder, Daniel; Nordbeck, Peter; Zwingelstein, Christian; Morand, Olivier; Welford, Richard W.D.; Dingemanse, Jasper; Wanner, Christoph Journal: Clinical pharmacology & therapeutics Issue: Volume 103:Issue 4(2018) Page Start: 703 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma. Issue 1 (2nd October 2021) Authors: Weathers, Shiao-Pei; Rood-Breithaupt, Julie; de Groot, John; Thomas, Gail; Manfrini, Marianna; Penas-Prado, Marta; Puduvalli, Vinay K; Zwingelstein, Christian; Yung, W K Alfred Journal: Neuro-oncology advances Issue: Volume 3:Issue 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma. Issue 1 (2nd October 2021) Authors: Weathers, Shiao-Pei; Rood-Breithaupt, Julie; de Groot, John; Thomas, Gail; Manfrini, Marianna; Penas-Prado, Marta; Puduvalli, Vinay K; Zwingelstein, Christian; Yung, W K Alfred Journal: Neuro-oncology advances Issue: Volume 3:Issue 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma. Issue 1 (2nd October 2021) Authors: Weathers, Shiao-Pei; Rood-Breithaupt, Julie; de Groot, John; Thomas, Gail; Manfrini, Marianna; Penas-Prado, Marta; Puduvalli, Vinay K; Zwingelstein, Christian; Yung, W K Alfred Journal: Neuro-oncology advances Issue: Volume 3:Issue 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma. Issue 1 (2nd October 2021) Authors: Weathers, Shiao-Pei; Rood-Breithaupt, Julie; de Groot, John; Thomas, Gail; Manfrini, Marianna; Penas-Prado, Marta; Puduvalli, Vinay K; Zwingelstein, Christian; Yung, W K Alfred Journal: Neuro-oncology advances Issue: Volume 3:Issue 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗